PCSK9 and Hypercholesterolemia: Another important gene in ACVD is proprotein convertase subtilisin/kexin type 9 (PCSK9), a negative regulator of LDLR, which has become a key therapeutic target for the regulation of LDL-C in the most severe forms of clinical hypercholesterolaemia.